Y-79Homo sapiens (Human)Cancer cell line

Also known as: GM01232E, GM01232, Y79

🤖 AI SummaryBased on 19 publications

Quick Overview

Human retinoblastoma cell line with RB1 mutations and MYCN amplification.

Detailed Summary

The Y-79 cell line is a human retinoblastoma cell line derived from a retinoblastoma tumor. It is characterized by mutations in the RB1 gene and amplification of the MYCN gene. These genetic alterations are associated with aggressive tumor behavior and poor prognosis. Y-79 cells are commonly used in research to study retinoblastoma biology, including mechanisms of tumorigenesis, drug resistance, and therapeutic strategies. The cell line has been utilized in various studies to investigate the role of specific genes and pathways in retinoblastoma progression. Y-79 cells exhibit characteristics of retinoblastoma tumors, making them a valuable model for preclinical studies.

Research Applications

RB1 mutation analysisMYCN amplification studiesDrug resistance mechanismsTumor progression modelingTherapeutic target identification

Key Characteristics

RB1 mutationsMYCN amplificationRetinoblastoma tumor characteristicsIn vitro model for retinoblastoma research

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1893
Species	Homo sapiens (Human)
Tissue Source	Eye, globe[UBERON:UBERON_0010230]

Donor Information

Age	2
Age Category	Pediatric
Sex	Female

Disease Information

Disease	Retinoblastoma
Lineage	Eye
Subtype	Retinoblastoma
OncoTree Code	RBL

DepMap Information

Source Type	ATCC
Source ID	ACH-001295_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationUnexplicit	RB1	IVS20+1G>A	Heterozygous	-	from parent cell line Y-79
MutationUnexplicit	RB1	Ex2-6del	Heterozygous	-	from parent cell line Y-79

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

11,12

D13S317

11,12

D16S539

13,14

D18S51

13,16

D19S433

D21S11

30,32

D2S1338

D3S1358

15,16

D5S818

D7S820

8,9

D8S1179

13,16

FGA

20,22

Penta D

Penta E

13,18

TH01

TPOX

vWA

15,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism.

Zhao J.-Y., Wang L.-W., Shao R.-G., Li L.

BMC Ophthalmol. 20:92.1-92.11(2020).

DOI PubMed PMC

Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.

Aubry A., Yu T., Bremner R.

Cell Death Discov. 6:2.1-2.12(2020).

DOI PubMed PMC

Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.

Schramm A., Temming P., Steenpass L.

Exp. Cell Res. 375:92-99(2019).

DOI PubMed

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines.

Busch M.A., Papior D., Stephan H., Dunker N.

Oncol. Rep. 39:160-172(2018).

DOI PubMed PMC

In vitro characterization of CD133(lo) cancer stem cells in retinoblastoma Y79 cell line.

Vemuganti G.K.

BMC Cancer 17:779.1-779.12(2017).

DOI PubMed PMC

A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression.

te Riele H., Cloos J., Dorsman J.C.

PLoS ONE 11:E0153323-E0153323(2016).

DOI PubMed PMC

Targeting survivin enhances chemosensitivity in retinoblastoma cells and orthotopic tumors.

Gomer C.J.

PLoS ONE 11:E0153011-E0153011(2016).

DOI PubMed PMC

Re-characterization of established human retinoblastoma cell lines.";

Busch M.A., Philippeit C., Weise A., Dunker N.

Histochem. Cell Biol. 143:325-338(2015).

DOI PubMed

Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.

Lancet Oncol. 14:327-334(2013).

DOI PubMed

Full-length transcriptome analysis of human retina-derived cell lines ARPE-19 and Y79 using the vector-capping method.

Toyama S., Usami R., Ohtoko K., Kato S.

Invest. Ophthalmol. Vis. Sci. 52:6662-6670(2011).

DOI PubMed

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOI PubMed PMC

Differential CRX and OTX2 expression in human retina and retinoblastoma.

Glubrecht D.D., Kim J.-H., Russell L., Bamforth J.S., Godbout R.

J. Neurochem. 111:250-263(2009).

DOI PubMed PMC

Comparative genomic hybridization analysis of newly established retinoblastoma cell lines of adherent growth compared with Y79 of nonadherent growth.

Kim J.H., Kim J.H., Yu Y.S., Kim D.H., Kim Y.K., Kim K.-W.

J. Pediatr. Hematol. Oncol. 30:571-574(2008).

DOI PubMed

Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses.

Gallie B.L., Squire J.A.

Cancer Genet. Cytogenet. 179:102-111(2007).

DOI PubMed

Amplification of a DEAD box protein gene in retinoblastoma cell lines.

Godbout R., Squire J.A.

Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993).

DOI PubMed PMC

Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.

Kunikane H., Tanaka Y.

J. Cancer Res. Clin. Oncol. 121:729-738(1995).

DOI PubMed

Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells.

Ohashi Y., Sasabe T., Nishida T., Nishi Y., Higashi H.

Am. J. Ophthalmol. 96:321-325(1983).

DOI PubMed

Homogeneously staining region in a retinoblastoma cell line: relevance to tumor initiation and progression.

Nichols W.W.

J. Natl. Cancer Inst. 67:301-306(1981).

DOI PubMed

Characteristics of an established cell line of retinoblastoma.";

Tralka T.S., Wilcox J.L.

J. Natl. Cancer Inst. 53:347-360(1974).

DOI PubMed

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

DOI PubMed

Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79.

Lee W.-H.

Proc. Natl. Acad. Sci. U.S.A. 85:6017-6021(1988).

DOI PubMed PMC

Mechanism of i(6p) formation in retinoblastoma tumor cells.";

Horsthemke B., Greger V., Becher R., Passarge E.

Cancer Genet. Cytogenet. 37:95-102(1989).

DOI PubMed

Retinoblastoma cell lines Y79, RB355 and WERI-Rb27 are genetically related.

Madreperla S.A., Bookstein R., Jones O.W., Lee W.-H.

Ophthalmic Paediatr. Genet. 12:49-56(1991).

DOI PubMed

Scanning electron microscopic observation of two retinoblastoma cell lines.

McFall R.C., Nagy R.M., Nagle B.T., McGreevy L.M.

Cancer Res. 38:2827-2835(1978).

PubMed

Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.

Higuchi H., Uei Y.

Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).

DOI

Evaluation of cell doubling time in C6 and Y79 cell lines based on seeding density.

Kuduvalli S.S., Ramalakshmi O., Precilla S.D., Anitha T.S.

SBV J. Basic Clin. Appl. Heatlh Sci. 2:146-149(2019).

DOI

Generation of etoposide-resistant subline of human retinoblastoma Y79 cells and preliminary study of its resistance mechanism.

Shao R.-G., Li L., Zhao J.-Y.

Zhongguo Yiyao Sheng Wu Jishu 12:297-302(2017).

DOI

Anecdotal Information

Named Y-79 because it was the result of the 79th attempt of a group at Yale to establish a retinoblastoma cell line